Leerink Partnrs Issues Negative Estimate for BMY Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Leerink Partnrs cut their Q3 2025 EPS estimates for Bristol Myers Squibb in a research note issued to investors on Wednesday, July 9th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $1.67 per share for the quarter, down from their prior forecast of $1.69. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Leerink Partnrs also issued estimates for Bristol Myers Squibb’s Q4 2025 earnings at $1.65 EPS, FY2028 earnings at $5.57 EPS and FY2029 earnings at $6.07 EPS.

Other equities research analysts also recently issued research reports about the stock. UBS Group reduced their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. The Goldman Sachs Group reiterated a “neutral” rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a research report on Tuesday, April 8th. Piper Sandler began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target on the stock. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $55.00 price target on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $57.69.

Bristol Myers Squibb Stock Up 1.8%

Shares of NYSE:BMY opened at $48.54 on Thursday. Bristol Myers Squibb has a 52 week low of $39.93 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.17 and a current ratio of 1.28. The company’s fifty day moving average is $47.58 and its 200-day moving average is $53.35. The company has a market capitalization of $98.78 billion, a PE ratio of 18.18, a P/E/G ratio of 1.41 and a beta of 0.36.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the company earned ($4.40) earnings per share. The business’s revenue was down 5.6% compared to the same quarter last year.

Institutional Trading of Bristol Myers Squibb

Institutional investors and hedge funds have recently modified their holdings of the stock. Pinney & Scofield Inc. bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Park Square Financial Group LLC bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $26,000. Global Wealth Strategies & Associates increased its stake in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares in the last quarter. Transce3nd LLC bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. Finally, Fairway Wealth LLC bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $28,000. 76.41% of the stock is owned by institutional investors.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was bought at an average cost of $47.58 per share, with a total value of $202,215.00. Following the purchase, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 0.09% of the stock is currently owned by company insiders.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be paid a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.11%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.